CN113640420A - 血清代谢物组合在胰腺癌早期诊断中的应用 - Google Patents
血清代谢物组合在胰腺癌早期诊断中的应用 Download PDFInfo
- Publication number
- CN113640420A CN113640420A CN202110929066.9A CN202110929066A CN113640420A CN 113640420 A CN113640420 A CN 113640420A CN 202110929066 A CN202110929066 A CN 202110929066A CN 113640420 A CN113640420 A CN 113640420A
- Authority
- CN
- China
- Prior art keywords
- serum
- pancreatic cancer
- alanine
- aspartic acid
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002966 serum Anatomy 0.000 title claims abstract description 61
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 51
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 51
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 51
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 51
- 239000002207 metabolite Substances 0.000 title claims abstract description 50
- 238000013399 early diagnosis Methods 0.000 title claims abstract description 19
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 26
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims abstract description 25
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims abstract description 25
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 25
- 229960003767 alanine Drugs 0.000 claims abstract description 25
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims abstract description 23
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims abstract description 23
- 229960005261 aspartic acid Drugs 0.000 claims abstract description 23
- 229950009148 androstenediol Drugs 0.000 claims abstract description 20
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims abstract description 20
- STKYPAFSDFAEPH-LURJTMIESA-N glycylvaline Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 claims abstract description 20
- 238000001514 detection method Methods 0.000 claims abstract description 17
- 238000003745 diagnosis Methods 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims abstract description 7
- 230000035945 sensitivity Effects 0.000 claims abstract description 7
- 238000007619 statistical method Methods 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 5
- 239000008280 blood Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 7
- 238000007477 logistic regression Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 230000005686 electrostatic field Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 abstract description 9
- 238000012216 screening Methods 0.000 abstract description 9
- 230000002503 metabolic effect Effects 0.000 abstract description 6
- 238000003766 bioinformatics method Methods 0.000 abstract description 3
- 238000003759 clinical diagnosis Methods 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- YWYQTGBBEZQBGO-XFHAOOBSSA-N (3s,5s,8r,9s,10s,13s,14s,17s)-17-[(1r)-1-hydroxyethyl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](O)C)[C@@]2(C)CC1 YWYQTGBBEZQBGO-XFHAOOBSSA-N 0.000 description 1
- 102400001063 Fibrinopeptide B Human genes 0.000 description 1
- 101800003778 Fibrinopeptide B Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000020241 Neonatal disease Diseases 0.000 description 1
- 208000037129 Newborn Diseases Infant Diseases 0.000 description 1
- YWYQTGBBEZQBGO-UHFFFAOYSA-N UC1011 Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(O)C)C1(C)CC2 YWYQTGBBEZQBGO-UHFFFAOYSA-N 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- MYRIFIVQGRMHRF-OECXYHNASA-N fibrinopeptide b Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 MYRIFIVQGRMHRF-OECXYHNASA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- -1 small molecule metabolites of L-aspartic acid Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
Landscapes
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Library & Information Science (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110929066.9A CN113640420B (zh) | 2021-08-13 | 2021-08-13 | 血清代谢物组合在胰腺癌早期诊断中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110929066.9A CN113640420B (zh) | 2021-08-13 | 2021-08-13 | 血清代谢物组合在胰腺癌早期诊断中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113640420A true CN113640420A (zh) | 2021-11-12 |
CN113640420B CN113640420B (zh) | 2023-05-02 |
Family
ID=78421420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110929066.9A Active CN113640420B (zh) | 2021-08-13 | 2021-08-13 | 血清代谢物组合在胰腺癌早期诊断中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113640420B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110282587A1 (en) * | 2010-05-17 | 2011-11-17 | Emory University | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry |
US20120308646A1 (en) * | 2007-01-18 | 2012-12-06 | Hesheng Zhang | Tetracyclic anthraquinones possessing anti-cancer properties |
CN105572276A (zh) * | 2014-11-07 | 2016-05-11 | 上海市第六人民医院 | 胰腺癌诊断标记物组合、应用及其测定方法 |
CN109239210A (zh) * | 2018-09-10 | 2019-01-18 | 哈尔滨工业大学 | 一种胰腺导管腺癌标志物及其筛选方法 |
CN110646554A (zh) * | 2019-09-12 | 2020-01-03 | 北京博远精准医疗科技有限公司 | 基于代谢组学的胰腺癌诊断标志物及其筛选方法和应用 |
-
2021
- 2021-08-13 CN CN202110929066.9A patent/CN113640420B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120308646A1 (en) * | 2007-01-18 | 2012-12-06 | Hesheng Zhang | Tetracyclic anthraquinones possessing anti-cancer properties |
US20110282587A1 (en) * | 2010-05-17 | 2011-11-17 | Emory University | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry |
CN105572276A (zh) * | 2014-11-07 | 2016-05-11 | 上海市第六人民医院 | 胰腺癌诊断标记物组合、应用及其测定方法 |
CN109239210A (zh) * | 2018-09-10 | 2019-01-18 | 哈尔滨工业大学 | 一种胰腺导管腺癌标志物及其筛选方法 |
CN110646554A (zh) * | 2019-09-12 | 2020-01-03 | 北京博远精准医疗科技有限公司 | 基于代谢组学的胰腺癌诊断标志物及其筛选方法和应用 |
Non-Patent Citations (2)
Title |
---|
SHIBANI S. MUKERJI等: "Low Neuroactive Steroids Identifies a Biological Subtype of Depression in Adults with Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy", 《THE JOURNAL OF INFECTIOUS DISEASES》 * |
林贤超等: "胰腺癌核磁共振血清代谢组学分析", 《中华消化外科杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN113640420B (zh) | 2023-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6443937B2 (ja) | 膵癌用唾液バイオマーカー、及び、これを用いた膵癌患者を健常者から識別する方法 | |
EP2398918B1 (en) | Methods for diagnosis and prognosis of colorectal cancer | |
EP3208614B1 (en) | Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer by using same | |
EP3019624B1 (en) | Biomarkers of autism spectrum disorder | |
US10330682B2 (en) | Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using same | |
EP3535587B1 (en) | Mass spectrometry-based methods for the detection of circulating histones h3 and h2b in plasma from sepsis or septic shock (ss) patients | |
CN112924608A (zh) | 一种用于糖尿病早期诊断的多肽标志物及检测试剂盒和方法 | |
KR102569168B1 (ko) | 폐암 진단용 바이오마커 및 폐암 진단에 대한 인공지능 기반 정보 제공 방법 | |
CN113640420B (zh) | 血清代谢物组合在胰腺癌早期诊断中的应用 | |
CN112924690B (zh) | 用于预警和/或诊断糖尿病的血清多肽组合标志物及检测试剂盒和方法 | |
EP2339352A1 (en) | Use of endogenous metabolites for early diagnosing sepsis | |
CN112924692B (zh) | 一种基于多肽定量测定的糖尿病诊断试剂盒及其方法 | |
CN112924689B (zh) | 基于多肽组合标志物定量测定的糖尿病诊断试剂盒及其方法 | |
US20190128901A1 (en) | Method for the Diagnosis of Cystic Fibrosis | |
CN113866285B (zh) | 用于糖尿病诊断的生物标志物及其应用 | |
Dewulf et al. | DBS are suitable for 1, 5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia | |
Cascant-Vilaplana et al. | Longitudinal perturbations of plasma nuclear magnetic resonance profiles in neonatal encephalopathy | |
CN112924688B (zh) | 多肽组合标志物在糖尿病诊断中的用途及其试剂盒和方法 | |
CN112924687B (zh) | 基于多肽组合标志物的糖尿病诊断试剂盒及其方法 | |
CN112924691B (zh) | 一种用于糖尿病早期诊断的多肽组合标志物及检测试剂盒和方法 | |
CN114137192B (zh) | 7-甲基黄嘌呤作为检测靶点在制备2型糖尿病高危个体筛查试剂盒中的应用 | |
KR102700025B1 (ko) | 결핵의 대사체 바이오마커 | |
US20220283163A1 (en) | Biomarkers for Detecting Secondary Liver Cancer | |
EP4372382A1 (en) | Methods for colorectal cancer diagnosis and prognosis | |
KR101862638B1 (ko) | 호모시스테인을 이용한 급성관상동맥증후군후 우울증발병여부 진단방법 및 진단키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240723 Address after: 197 Ruijin 2nd Road, Huangpu District, Shanghai 200025 Patentee after: RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG University SCHOOL OF MEDICINE Country or region after: China Patentee after: SHANGHAI INSTITUTE OF ENDOCRINE AND METABOLIC DISEASES Address before: 197 Ruijin 2nd Road, Huangpu District, Shanghai 200025 Patentee before: SHANGHAI INSTITUTE OF ENDOCRINE AND METABOLIC DISEASES Country or region before: China |
|
TR01 | Transfer of patent right |